Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions. Read More
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY)
jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Myers lifted its annual revenue guidance to a new midpoint of $47.75 billion. The market reacted positively to the earnings beat and improved outlook, signaling investor confidence in the company's performance.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi.
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.
Bristol Myers Squibb (NYSE:BMY) today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The company also announced new findings from an integrated analysis of the Phase 2 PAISLEY-SLE and PAISLEY long-term extension (LTE) studies supporting the safety and efficacy with up to four years of Sotyktu treatment for moderate-to-severe systemic lupus erythematosus (SLE).
Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its investigational, autologous CD19-targeted NEX-T™ CAR T cell therapy BMS-986353 (CC-97540). The data, evaluating a total of 71 treated patients across the systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM) cohorts, are being featured at the American College of Rheumatology (ACR) Convergence 2025, taking place from October 24-29 in Chicago, Illinois.
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from October 17-21 in Berlin, Germany. Data from more than 50 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 10 cancer types.
